Home › NCT06658002
Fungal Ulcer Treatment Augmented With Natamycin and Cyclosporine A
RecruitingPhase 3
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Inclusion is based on presenting acuity, not ulcer size. * Inclusion of 20/40 = 6/12 = 0.3 Log MAR and 20/400 = 3/60 = +1.3 Log MAR. * Smear or culture positive for fungal keratitis, any length. * Age 18 years. * Willing to participate in study. Exclusion Criteria: * Co-infection with bacterial or viral keratitis. * Corneal perforation. * Requiring therapeutic keratoplasty for fungal keratitis. * Unwilling or unable to follow up (e.g., living too far from hospital). * Presenting acuity better than 20/40 = 6/12 = 0.3 Log MAR or worse than 20/400 = 3/60 = +1.3 Log MAR. * Subjects taking cyclosporine at any concentration on presentation. * Acuity worse than 20/200 = 6/60 = +1.0 Log MAR in unaffected eye. * Pregnant women. * Penetrating Keratoplasty. * Presents with a 0-7 day history of topical steroid.
About the study
The goal of this clinical trial is to learn if adjunctive topical Cyclosporine A eye drops combined with standard of care topical Natamycin treatment improves vision outcomes in patients with fungal keratitis.
What is being tested
- Cyclosporine A (drug)
- Placebo Comparator: Placebo (other)
Sponsor: University of California, San Francisco · Participants: 150 · Started: Sep 1, 2025
Contact the study team
- Gerami D Seitzman, MD · Phone: 4154761442
Official record on ClinicalTrials.gov — NCT06658002
Locations in the U.S.
| California | University of California, San Farncisco, San Francisco (Not yet recruiting) |
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.